Early Phase 1 — Very small initial tests in humans, typically just a few people, to make sure the treatment is safe enough to study further.
Trial locations(2 sites)
United States
OculoMotor Technologies, Newark, New Jersey The Eye Institute at Salus University, Philadelphia, Pennsylvania